Clinical characteristics, alcohol intake and risk factors of male type 2 diabetes with coronary heart disease

To investigate the clinical characteristics, alcohol intake and risk factors of male patients with type 2 diabetes and coronary heart disease. 198 male patients with type 2 diabetes (T2DM) admitted to our hospital between October 2018 and January 2019 were selected as the T2DM group. 118 male patients with T2DM and coronary heart disease (CAD) admitted during the same period were selected as T2DM and CAD group. Collect the relevant clinical data of patients. The clinical characteristics of male patients with T2DM and CAD were analyzed using single factor analysis. An analysis of male patients’ risk factors for T2DM and CAD was conducted using binary logistic regression analysis. The risk probability model was constructed. Hosmer and Lemeshow were used to test the Goodness of fit of the probability model. ROC (receiver operating characteristic curve) curves were drawn with SPSS (Statistical Package For The Social Sciences) to evaluate the prediction model’s predictive value. T2DM with CAD patients were older, had longer diabetes duration, higher BMI (Body Mass Index), higher excess drinking proportion, higher hypertension proportion, higher LDL-C (Low-Density Lipoprotein Cholesterol) level, and higher FIB (Fibrinogen) than T2DM without CAD patients. Statistically significant differences were observed (p < 0.05). Age, BMI, diabetes duration, excessive drinking and hypertension are risk factors for coronary heart disease in male patients with T2DM. Compared with male patients with T2DM, male patients with T2DM and CAD are older, have longer durations of diabetes, have higher BMIs, excessive drinking and hypertension, and have higher levels of LDL-C and FIB. Age, BMI, diabetes duration, excessive drinking and hypertension are risk factors for male patients with T2DM and CAD. A clinical prognosis can be improved by giving early active intervention based on the risk situation of patients.

Male; Type 2 diabetes; Concomitant coronary heart disease; Clinical characteristics; Alcohol intake; Risk factors

[1] Liu Y, Liu J-E, He H, Qin M, Lei H, Meng J, et al. Characterizing the metabolic divide: distinctive metabolites differentiating CAD-T2DM from CAD patients. Cardiovascular Diabetology. 2024; 23: 14.

[2] Zhu T, Cui J, Goodarzi MO. Polycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and stroke. Diabetes. 2021; 70: 627–637.

[3] Hamedifard Z, Farrokhian A, Reiner Ž, Bahmani F, Asemi Z, Ghotbi M, et al. The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease. Lipids in Health and Disease. 2020; 19: 112.

[4] Aune SK, Byrkjeland R, Solheim S, Arnesen H, Trøseid M, Awoyemi A, et al. Gut related inflammation and cardiorespiratory fitness in patients with CAD and type 2 diabetes: a sub-study of a randomized controlled trial on exercise training. Diabetology & Metabolic Syndrome. 2021; 13: 36.

[5] Yang T, Liu Y, Li L, Zheng Y, Wang Y, Su J, et al. Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and type 2 diabetes in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovascular Diabetology. 2022; 21: 93.

[6] Goodarzi MO, Rotter JI. Genetics insights in the relationship between type 2 diabetes and coronary heart disease. Circulation Research. 2020; 126: 1526–1548.

[7] Konerding U, Redaèlli M, Ackermann K, Altin S, Appelbaum S, Biallas B, et al. A pragmatic randomised controlled trial referring to a Personalised Self-management SUPport Programme (P-SUP) for persons enrolled in a disease management programme for type 2 diabetes mellitus and/or for coronary heart disease. Trials. 2021; 22: 659.

[8] Xiao H, Ma Y, Zhou Z, Li X, Ding K, Wu Y, et al. Disease patterns of coronary heart disease and type 2 diabetes harbored distinct and shared genetic architecture. Cardiovasc Diabetol. 2022; 21: 276.

[9] Kalashnikov VI, Michurova MS. New opportunities of antithrombotic therapy in patients with type 2 diabetes mellitus and stable coronary heart disease for reducing the cardiovascular risk and cardiovascular complications: THEMIS, THEMIS-PCI trials. Therapeutic Archive. 2022; 94: 1204–1210. (In Russian)

[10] Tamlander M, Mars N, Pirinen M, Widén E, Ripatti S. Integration of questionnaire-based risk factors improves polygenic risk scores for human coronary heart disease and type 2 diabetes. Communications Biology. 2022; 5: 158.

[11] Xie Q, Huang J, Zhu K, Chen Q. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with coronary heart disease and type 2 diabetes mellitus: cumulative meta-analysis. Clinical Cardiology. 2021; 44: 899–906.

[12] Tian X, Gao Y, Zhong M, Kong M, Zhao L, Feng Z, et al. The association between serum Sestrin2 and the risk of coronary heart disease in patients with type 2 diabetes mellitus. BMC Cardiovascular Disorders. 2022; 22: 281.

[13] Meng XM, Kang SX, Li J, Zhang HT, Li M. Clinical significance of N-terminal natriuretic peptide combined with inflammatory factors, oxidative stress factors and blood lipid detection in elderly patients with type-2 diabetes complicated with coronary heart disease. Pakistan Journal of Medical Sciences. 2022; 38: 1310–1315.

[14] Mayr HL, Kelly JT, Macdonald GA, Russell AW, Hickman IJ. Clinician perspectives of barriers and enablers to implementing the mediterranean dietary pattern in routine care for coronary heart disease and type 2 diabetes: a qualitative interview study. Journal of the Academy of Nutrition and Dietetics. 2022; 122: 1263–1282.

[15] Ferguson LD, Linge J, Dahlqvist Leinhard O, Woodward R, Hall Barrientos P, Roditi G, et al. Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity—a cross-sectional study. Rheumatology. 2021; 60: 1858–1862.

[16] Gao B, Gao W, Wan H, Xu F, Zhou R, Zhang X, et al. Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: a multicentre, randomized, open-label, prospective study (ACADEMIC). Diabetes, Obesity and Metabolism. 2022; 24: 991–999.

[17] Afanas’ev SA, Kondrat’eva DS, Muslimova EF, Budnikova OV, Akhmedov SD, Kozlov BN. Expression of genes and proteins of the sarcoplasmic reticulum Са2+-transport systems in cardiomyocytes in concomitant coronary heart disease and type 2 diabetes mellitus. Bulletin of Experimental Biology and Medicine. 2021; 172: 117–120.

[18] Boronat M. NOS3 RS1799983 and RS2070744 Polymorphisms and their association with advanced chronic kidney disease and coronary heart disease in canarian population with type 2 diabetes. Acta Endocrinologica. 2021; 17: 440–448.

[19] Xu S, Scott CAB, Coleman RL, Tuomilehto J, Holman RR. Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance. Journal of Diabetes. 2021; 13: 817–826.

[20] Yubero-Serrano EM, Alcalá-Diaz JF, Gutierrez-Mariscal FM, Arenas-de Larriva AP, Peña-Orihuela PJ, Blanco-Rojo R, et al. Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study. Cardiovascular Diabetology. 2021; 20: 72.